1. Home
  2. ORIS vs OGEN Comparison

ORIS vs OGEN Comparison

Compare ORIS & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ORIS

Oriental Rise Holdings Limited Ordinary Shares

HOLD

Current Price

$1.52

Market Cap

3.7M

ML Signal

HOLD

Logo Oragenics Inc.

OGEN

Oragenics Inc.

HOLD

Current Price

$0.78

Market Cap

3.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ORIS
OGEN
Founded
2014
1996
Country
China
United States
Employees
N/A
N/A
Industry
Farming/Seeds/Milling
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.7M
3.6M
IPO Year
2024
N/A

Fundamental Metrics

Financial Performance
Metric
ORIS
OGEN
Price
$1.52
$0.78
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
180.5K
96.1K
Earning Date
04-30-2026
11-07-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.01
N/A
Revenue
$12,317,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$163.69
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.14
$0.74
52 Week High
$57.00
$18.90

Technical Indicators

Market Signals
Indicator
ORIS
OGEN
Relative Strength Index (RSI) 96.29 35.86
Support Level $0.06 $0.82
Resistance Level $0.11 $0.88
Average True Range (ATR) 0.05 0.05
MACD 0.13 0.00
Stochastic Oscillator 85.91 18.00

Price Performance

Historical Comparison
ORIS
OGEN

About ORIS Oriental Rise Holdings Limited Ordinary Shares

Oriental Rise Holdings Ltd is an integrated supplier of tea products in China. It is principally engaged in the business of planting, cultivating, processing, and selling processed tea. The company currently produces and sells three categories of products: roughly processed white tea, roughly processed black tea, and refined tea. The company's business operations are vertically integrated, covering cultivation, processing of tea leaves, and the sale of tea products to tea business operators and end-user retail customers. Geographically, the company generates all of its revenue from its business in the People's Republic of China (the PRC).

About OGEN Oragenics Inc.

Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.

Share on Social Networks: